Influence of patient co-payments on atypical antipsychotic choice in Poland: Implications once generic atypicals are available

Applied Health Economics and Health Policy

Volumn 9, Issue 2, 2011, Pages 101-110

  Wladysiuk, Magda ^a   Araszkiewicz, Aleksander ^b   Godman, Brian ^c,d,e   Szabert, Katarzyna ^b   Barbui, Corrado ^f   Haycox, Alan ^d  

^a HTA CONSULTING   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF VERONA   (Italy)

Author keywords

Antipsychotics general; Co payment; Cost analysis; Drug utilisation; Generic substitution; Pricing

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GENERIC DRUG; LIOXAM; MEPHARIS; OLANZAPINE; RISPERIDONE; RISSET; RYSPOLIT; SPERIDAN; UNCLASSIFIED DRUG; ZOLAFREN;

ARTICLE; DRUG COST; DRUG FORMULATION; DRUG UTILIZATION; FUNDING; HUMAN; POLAND; PRESCRIPTION; QUALITY OF LIFE; REIMBURSEMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHEMISTRY, PHARMACEUTICAL; CHOICE BEHAVIOR; COST SHARING; DRUG PRESCRIPTIONS; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PHYSICIAN'S PRACTICE PATTERNS; POLAND; RISPERIDONE;

EID: 79951916833     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11318840-000000000-00000     Document Type: Article

References (45)

1. Knapp M, Kanavos P, King D, et al. Economic issues in access to medications: schizophrenia treatment in England. Int J Law Psychiatry 2005; 28: 514-31 (Pubitemid 41338403)
2. Andretta M, Ciuna A, Corbari L, et al. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 72-7 (Pubitemid 40069175)
3. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf 2006; 15: 412-20 (Pubitemid 44018700)
4. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff 2009; 28 (5): w770-81
5. Mond J, Morice R, Owen C, et al. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55-61
6. Leucht S, Corvers C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373 (9657): 31-41
7. Ren XS, Qian S, Lee AF, et al. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther 2006; 31: 57-65
8. Taylor DM, Wright T, Libretto S. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003; 64: 589-97 (Pubitemid 36618290)
9. Valenstein M, Blow FC,Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-64 (Pubitemid 38828533)
10. Walley T. Neuropsychotherapeutics in the UK. What has been the impact of NICE on prescribing? CNS Drugs 2004; 18 (1): 1-12 (Pubitemid 38197755)
11. National Institute for Health andClinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. London: 2009 Mar, NICE [online]. Available from URL: ttp://www.nice.org.uk/nicemedia/live/11786/43608/43608.pdf [Accessed 2010 Nov 10]
12. Barbui C, Lintas C, Percudani M. Head-to-head comparison of the cost of atypical antipsychotics: a systematic review. CNS Drugs 2005; 19 (1): 935-50 (Pubitemid 41571993)
13. Gardner D, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172 (13): 1703-11 (Pubitemid 40896865)
14. Rosenheck R, SwartzM,McEvoy J, et al. Second-generation antispychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Rev Pharmacoecon Outcomes Res 2007; 7 (2): 103-11 (Pubitemid 46681857)
15. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361 (9369): 1581-9 (Pubitemid 36578993)
16. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373 (9657): 4-5
17. Magnus A, Carr V, Mihalopoulos C, et al. Assessing costeffectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 2005; 39 (1-2): 44-54 (Pubitemid 40277434)
18. Hargreaves WA, Gibson JP. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 2005; 19 (5): 393-410 (Pubitemid 41124014)
19. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-94 (Pubitemid 44480836)
20. Liu GG, Sun SX, Christensen DB, et al. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann Pharmacother 2004; 38: 134-41 (Pubitemid 38018019)
21. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2006
22. Soumerai SB,McLaughlin TJ,Ross-Degnan D, et al. Effects of a limit onMedicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331 (10): 650-5 (Pubitemid 24276866)
23. Zeber J, Grazier KL, Valenstein M, et al. Effect of a medication copayment increase in veterans with schizophrenia. Am J Manag Care 2007; 13: 335-46 (Pubitemid 46983130)
24. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007; 23: 2305-12 (Pubitemid 350033432)
25. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008; 34: 173-80 (Pubitemid 350262282)
26. Atella V, Schafheutle E, Noyce P, et al. Affordability of medicines and patients' cost-reducing behaviour. Appl Health Econ Health Policy 2006; 4 (1): 23-35
27. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005; 14: 341-8 (Pubitemid 40716327)
28. Araszkiewicz AA, Szabert K, Godman B, et al. Generic olanzapine: health authority opportunity or nightmare? Expert Rev Pharmacoecon Outcomes Res 2008; 8 (6): 549-55
29. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010; 70 (3): 335-41
30. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26 (2): 91-8
31. Ferner R, Lenney W, Marriott J. Controversy over generic substitution. BMJ 2010; 340: c2548
32. Chaplin S, Duerdin M. When brands are best: brand versus generic prescribing. Chichester: John Wiley & Sons Ltd, 2006
33. Goldman D, Joyce G, Zheng Y. Prescription drug cost sharing: associations with medication and medication utilization and spending and health. JAMA 2007; 298 (1): 61-9 (Pubitemid 47026771)
34. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20: 307-28 (Pubitemid 41762889)
35. Garattini L, Ghislandi S. Off-patent drugs in Italy: a short sighted view? Eur J Health Econ 2006; 7: 79-83
36. Godman B, Shrank W, Wettermark B, et al. Use of generics: a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 2010; 3: 2470-94
37. Whisky E, Taylor D. Generic clozapine: opportunity or threat? Pharmaceutical J 2004; 273: 112 (Pubitemid 39144522)
38. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res 2008; 8 (4): 357-71
39. Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009; 9 (5): 475-84
40. Godman B, Buscics A, Burkhardt T, et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2010; 10 (2): 199-207
41. Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010; 8 (1): 7-24
42. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risksharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010 Jun 7; 10: 153
43. Law of 27 August 2004 on health care services financed from public funds (with all amendments) [online]. Available from URL: http://isip.sejm.gov.pl/ DetailsServlet?id=WDU 20042102135 [Accessed 2010 Nov 10]
44. Wagner TH, Heisler M, Piette JD. Prescription drug copayments and cost-related medication underuse. Health Econ Policy Law 2008; 3 (1): 51-67 (Pubitemid 351283145)
45. Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008 Jan 23; (1): CD007017